The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy.
cancer
checkpoint inhibitor therapy
glucocorticoids
immunosuppressants
immunotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
05
2022
accepted:
19
07
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs). Moderate to severe irAEs are typically treated with glucocorticoids, sometimes with the addition of immunosuppressants as steroid-sparing therapy. However, it is unclear how glucocorticoids and immunosuppressants may impact cancer survival and the efficacy of immune checkpoint therapy on cancer. In this narrative review, we discuss the effects of glucocorticoids and immunosuppressants including methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, tumor-necrosis factor (TNF)-inhibitors, interleukin-6 inhibitors, interleukin-1 inhibitors, abatacept, rituximab, and Janus kinase inhibitors (JAKi) on cancer-specific outcomes in the setting of immune checkpoint inhibitor use.
Identifiants
pubmed: 36081549
doi: 10.3389/fonc.2022.928390
pmc: PMC9445222
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
928390Informations de copyright
Copyright © 2022 Bruera and Suarez-Almazor.
Déclaration de conflit d'intérêts
Author MS-A has received consultant fees from participation on advisory boards for Gilead, Avenue Therapeutics, ChemoCentryx. Current member of advisory board for Celgene. All activities unrelated to this work. The remaining author declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Dermatitis. 2021 Aug 16;:
pubmed: 34405836
Eur J Cancer. 2021 Nov;157:214-224
pubmed: 34536945
J Clin Oncol. 2021 Dec 20;39(36):4073-4126
pubmed: 34724392
Oncoimmunology. 2020 Oct 5;9(1):1824645
pubmed: 33101774
J Immunother. 2019 Jun;42(5):175-179
pubmed: 31090656
Eur Heart J Case Rep. 2021 Aug 18;5(11):ytab342
pubmed: 34870082
J Clin Oncol. 1988 Aug;6(8):1328-34
pubmed: 3411344
Eur J Cancer. 2021 Mar;145:245-254
pubmed: 33419647
Rheumatology (Oxford). 2022 May 5;61(5):1810-1818
pubmed: 34324640
Molecules. 2021 Sep 24;26(19):
pubmed: 34641331
Mod Rheumatol Case Rep. 2022 Jan 7;6(1):36-40
pubmed: 34505624
Arthritis Rheumatol. 2021 May;73(5):866-874
pubmed: 33258544
Rheum Dis Clin North Am. 2020 Aug;46(3):445-462
pubmed: 32631599
Rheumatology (Oxford). 2020 Sep 1;59(9):2360-2367
pubmed: 31880308
Nature. 2019 May;569(7756):428-432
pubmed: 31043740
Cancer Cell. 2020 Oct 12;38(4):500-515.e3
pubmed: 32916126
Biomark Res. 2022 Jan 27;10(1):5
pubmed: 35086565
J Immunother Cancer. 2018 May 11;6(1):37
pubmed: 29747688
J Oncol Pharm Pract. 2019 Apr;25(3):551-557
pubmed: 29207939
Eur J Intern Med. 2021 Nov;93:87-94
pubmed: 34391591
Clin Rheumatol. 2019 May;38(5):1513-1519
pubmed: 30701346
J Immunother Cancer. 2019 Jun 14;7(1):153
pubmed: 31200747
Am J Clin Exp Immunol. 2021 Dec 15;10(4):93-102
pubmed: 35106186
J Exp Med. 2019 Dec 2;216(12):2701-2713
pubmed: 31537643
J Cancer Res Clin Oncol. 2011 Apr;137(4):577-83
pubmed: 20512382
J Rheumatol. 2020 Feb;47(2):166-175
pubmed: 31308203
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
N Engl J Med. 2022 Jan 27;386(4):316-326
pubmed: 35081280
J Clin Oncol. 2007 Oct 10;25(29):4542-9
pubmed: 17925549
Future Oncol. 2021 Apr;17(12):1459-1472
pubmed: 33648347
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Nat Med. 1999 Jul;5(7):828-31
pubmed: 10395330
JAMA Intern Med. 2017 Nov 1;177(11):1605-1612
pubmed: 28975211
Melanoma Res. 2012 Aug;22(4):287-93
pubmed: 22617301
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35086945
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33007977
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581042
Anticancer Res. 2020 Apr;40(4):2209-2217
pubmed: 32234916
Br J Pharmacol. 2014 Oct;171(19):4337-59
pubmed: 24902607
Ann Intern Med. 2018 Sep 4;169(5):291-299
pubmed: 30105374
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120803
Cancers (Basel). 2021 May 14;13(10):
pubmed: 34068892
Clin Rheumatol. 2020 Oct;39(10):2943-2950
pubmed: 32803571
Nat Rev Rheumatol. 2021 Apr;17(4):213-223
pubmed: 33686279
Ann Oncol. 2008 Jul;19(7):1340-1346
pubmed: 18325912
Front Oncol. 2018 Jul 31;8:287
pubmed: 30109213
Front Oncol. 2020 Sep 07;10:1677
pubmed: 33014837
J Thorac Oncol. 2018 Nov;13(11):1771-1775
pubmed: 29935305
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34226279
Nat Commun. 2017 Dec 22;8(1):2256
pubmed: 29273790
N Engl J Med. 2019 Jun 13;380(24):2377-2379
pubmed: 31189043
Ann Rheum Dis. 2020 Mar;79(3):332-338
pubmed: 31540935
Autoimmun Rev. 2020 Aug;19(8):102595
pubmed: 32535092
ESMO Open. 2019 Feb 27;4(1):e000457
pubmed: 30964126
Clin Cancer Res. 2021 Feb 15;27(4):1037-1047
pubmed: 33272982
Int J Hematol. 2022 Feb;115(2):222-232
pubmed: 34797531
RMD Open. 2018 Aug 17;4(2):e000714
pubmed: 30167328
Steroids. 2016 Jul;111:84-88
pubmed: 26930575
Eur J Dermatol. 2015 Jan-Feb;25(1):36-44
pubmed: 25500362
Clin Cancer Res. 2019 Mar 1;25(5):1557-1563
pubmed: 30409824
Lancet. 2017 Oct 21;390(10105):1833-1842
pubmed: 28855077
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051
Front Immunol. 2021 Oct 05;12:733961
pubmed: 34675925
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
Clin Cancer Res. 2020 May 1;26(9):2268-2274
pubmed: 31988197